NR1H4 and papillary renal cell carcinoma: Controversially, FXR also stimulated the cell growth of renal adenocarcinoma cells by downregulating cyclin-dependent kinase (CDK) inhibitors p16/INK4a and p21/Cip1, but had no effect in the normal renal cell-derived cell line [130].